By Wayne Kuznar Over the past year, several publications in the peer-reviewed literature were worthy of influencing clinical practice.
By Phoebe Starr Tofacitinib (Xeljanz), an oral Janus kinase (JAK) inhibitor, is effective in the treatment of patients with rheumatoid arthritis (RA) whose disease has an inadequate response to previous treatment with biologic therapies, and the response with tofacitinib is maintained for 24 months.
By Phoebe Starr The goal of treating lupus is to induce improvement and maintain it, said Bevra Hahn, MD, Chief, Department of Rheumatology and Arthritis, University of California at Los Angeles.
By Wayne Kuznar Compliance with treat-to-target guidelines for rheumatoid arthritis (RA) results in fewer inpatient visits, shorter lengths of stay, and lower utilization of emergency department services without additional medical service costs despite more frequent follow-up with a rheumatologist, found Martin J. Bergman, MD, FACR, FACP, Chief, Division of Rheumatology, Taylor Hospital, Ridley Park, PA, and colleagues.
In November 2012, the US Food and Drug Administration (FDA) approved tofacitinib (Xeljanz; Pfizer) for adult patients with moderate-to-severe rheumatoid arthritis (RA) who do not adequately respond to or are intolerant of methotrexate.
Patients are more social media savvy than ever, with many seeking out Facebook pages, Twitter posts, and YouTube videos as sources of medical information.
Acknowledging that many website users increasingly access online content on their mobile electronic device, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has implemented responsive design to deliver the content from the most-viewed pages on its website for easy accessibility, scrolling, and viewing on the smaller portable devices.
Oregon’s Health Insurance Exchange, named Cover Oregon, received conditional approval from the Centers for Medicare & Medicaid Services to begin operating later this year.
The International Society of Exercise and Immunology (ISEI) issued a position statement last year on exercise and immune function.
By Wayne Kuznar Although biomarker progress is easily discernible in cardiology and oncology, researchers are only at the beginning of the long, winding road of biomarker discovery in lupus, said Mary K. Crow, MD, Physician-in-Chief, and Chair, Division of Rheumatology, and Director of the Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York City, at the 2012 meeting of the American College of Rheumatology.
Page 1 of 3
Results 1 - 10 of 23
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology